Big Pharma cashes in on HGH abuse

by David B. Caruso

An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies.

The crackdown, which began in 2006, reduced the illegal flow of unregulated supplies from China, India and Mexico. But since then, Big Pharma has been satisfying the steady desires of U.S. users and abusers, including many who take the drug in the false hope of delaying aging.

An AP analysis of pharmaceutical company data shows that from 2005 to 2011, inflation-adjusted sales of HGH were up 69 percent. During the same period, sales of the average prescription drug rose 12 percent.

Under U.S. law, HGH can only be dispensed for very rare conditions.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Data firm sees 2011 drug sales rising 5-7 percent

Oct 07, 2010

(AP) -- Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm ...

Global spending on drugs to slow through 2016

Jul 12, 2012

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

Recommended for you

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments